Akums Drugs & Pharmaceuticals has entered a partnership with Canada’s Triple Hair Group to exclusively license a patented treatment for androgenic alopecia in India. This collaboration aims to bring an innovative topical formulation to the Indian market.
The new treatment combines three active ingredients to address alopecia, a condition that affects millions in India and around the world. The topical solution aims to prevent hair loss, promote new hair growth, and improve hair thickness, providing a comprehensive approach for those dealing with hair thinning and baldness.
This formulation offers a convenient option for users who prefer topical treatments, potentially enhancing adherence and effectiveness for individuals facing hair loss.
Sanjeev Jain, Managing Director of Akums, noted that this partnership is a key step in expanding their dermatology offerings and delivering effective hair care solutions in India. Jean-Philippe Gravel, CEO of Triple Hair, added that Akums will play a vital role in the regulatory process, including an upcoming Phase III clinical trial in India, which they plan to initiate in the coming weeks to expedite the commercialization of Therapy-07.
Related topics:
- New Hair Salon Opening in Suwanee
- Jenna Fischer Opens Up About Hair Loss During Chemo and Family Support
- Free Wig Giveaway for Alopecia and Medical Hair Loss
